Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: A meta-analysis involving 17,600 subjects

Breast Cancer Research and Treatment

Volumn 122, Issue 2, 2010, Pages 521-525

  Qiu, Li Xin ^a   Yao, Lei ^b   Mao, Chen ^c   Yu, Ke Da ^a   Zhan, Ping ^d   Chen, Bo ^e   Yuan, Hui ^f   Zhang, Jian ^a   Xue, Kai ^a   Hu, Xi Chun ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d NANJING CHEST HOSPITAL   (China)

^e NANJING MEDICAL UNIVERSITY   (China)

^f ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; CYP1A2; Meta analysis; Polymorphism; Susceptibility

Indexed keywords

ADENOSINE; CYTIDINE; CYTOCHROME P450 1A2; CYP1A2 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; CODOMINANCE; DOMINANT INHERITANCE; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; PRIORITY JOURNAL; RECESSIVE INHERITANCE; BREAST TUMOR; CASE CONTROL STUDY; ENZYMOLOGY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; PHENOTYPE; RISK; RISK ASSESSMENT; RISK FACTOR;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS;

EID: 77955664568     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0731-4     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74-108.
2. Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78-85.
3. Yamazaki H, Shaw PM, Guengerich FP, Shimada T (1998) Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 11:659-665.
4. Nebert DW, Dalton TP (2006) The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6:947-960.
5. Tsuchiya Y, Nakajima M, Yokoi T (2005) Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227:115-124.
6. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ (2004) Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 279:23847-23850.
7. Nebert DW, McKinnon RA, Puga A (1996) Human drugmetabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273-280.
8. Eaton DL, Gallagher EP, Bammler TK, Kunze KL (1995) Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5:259-274.
9. Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C > A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449.
10. Han XM, Ouyang DS, Chen XP, Shu Y, Jiang CH, Tan ZR, Zhou HH (2002) Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 54:540-543.
11. Le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR (2005) Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomark Prev 14:1998-2003.
12. Long JR, Egan KM, Dunning L, Shu XO, Cai Q, Cai H, Dai Q, Holtzman J, Gao YT, Zheng W (2006) Population-based casecontrol study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk. Pharmacogenet Genomics 16:237-243.
13. Kotsopoulos J, Ghadirian P, El-Sohemy A, Lynch HT, Snyder C, Daly M, Domchek S, Randall S, Karlan B, Zhang P, Zhang S, Sun P, Narod SA (2007) The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers. Cancer Epidemiol Biomark Prev 16:912-916.
14. Takata Y, Maskarinec G, Le Marchand L (2007) Breast density and polymorphisms in genes coding for CYP1A2 and COMT: the multiethnic cohort. BMC Cancer 7:30.
15. Gulyaeva LF, Mikhailova ON, PustyInyak VO, Kim IV 4th, Gerasimov AV, Krasilnikov SE, Filipenko ML, Pechkovsky EV (2008) Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia. Adv Exp Med Biol 617:359-366.
16. Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird NM, Khuhaprema T, Brennan P, Boffetta P, Yoshida T (2009) Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer 125:837-843.
17. Shimada N, Iwasaki M, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, Kusama R, Hamada GS, Nishimoto IN, Iyeyasu H, Motola J Jr, Laginha FM, Kurahashi N, Tsugane S (2009) Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non- Japanese Brazilians. J Hum Genet 54:209-215.
18. MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2010) Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat 119:463-474.
19. Rebbeck TR, Troxel AB, Walker AH, Panossian S, Gallagher S, Shatalova EG, Blanchard R, Norman S, Bunin G, DeMichele A, Berlin M, Schinnar R, Berlin JA, Strom BL (2007) Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiol Biomark Prev 16:444-450.
20. Bågeman E, Ingvar C, Rose C, Jernström H (2008) Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status. Cancer Epidemiol Biomark Prev 17:895-901.
21. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101-129.
22. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748.
23. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
24. Tobias A (1998) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15-17.
25. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634.
26. Taylor SJ, Tweedie RI (1998) Practical estimates of the effect of publication bias in meta-analysis. Australas Epidemiol 5:14-17.
27. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR, Gooderham NJ (2003) Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 55:68-76.